All In Biotech

Drug Trial Radar · NCT06797401

Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jan 28, 2025

Primary completion

May 31, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Ribocure Pharmaceuticals ABIndustry
Sponsor type
Industry
First posted
Jan 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug RBD5044 works to treat mixed dyslipidemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are: Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat mixed dyslipidemia. Participants will: Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84). Visit the clinic 11 times during 12 months (visit every 4-8 weeks) for checkups and tests.

Conditions

  • Dyslipidemias

Interventions

  • RBD5044Drug

    RBD5044, active drug.

  • PlaceboDrug

    Placebo that is identical in appearance and volume to the doses of active IMP.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in triglyceride (TG) levels at week 16Time frame: From baseline until end week 16

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Linden Sp.

    Krakow, Poland · Recruiting

  • Balsam Medica Sp.

    Warsaw, Poland · Recruiting

  • Lunds Universitetssjukhus

    Lund, Sweden · Recruiting

  • Ribocure Clinic/Ribocure Pharmaceuticals AB

    Mölndal, Sweden · Recruiting

  • AkardoMedSite

    Stockholm, Sweden · Recruiting

  • Akademiska Sjukhuset Uppsala

    Uppsala, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.